Mawdsleys is now the sole distributor for all Ranbaxy contracted products
Mawdsleys is now the sole distributor for all Ranbaxy contracted products 3rd May 2016

As of 1st May 2016, Mawdsleys will become the sole distributor for all Ranbaxy contracted products into the hospital sector (as you may be aware, currently hospitals purchase Ranbaxy products directly). All products are now listed on Mawdsleys Online. To ensure continuity of supply all products can still be ordered through Ranbaxy directly until the end of May 2016.

 

 The full range of Ranbaxy products will available through Mawdsleys, and you will be able to;

 

Benefit from EDI or online ordering

View invoices online

View contract prices online

View Ranbaxy stock availability online

Benefit from no minimum order levels

Benefit from daily deliveries from your local depot

 

You can order your Ranbaxy products from Mawdsleys through your normal preferred route; i.e. fax, EDI, through the Mawdsleys online ordering system, Mawdsleys Online, or by calling your local depot.

 

Should you have any queries, please feel free to contact your local Mawdsleys Account Manager.

Other latest news
https://www.mawdsleys.co.uk/news/keeping-the-essentials-moving-during-contract-change-time/ thumbnail image Keeping the essentials moving during contract change time

Last week we sent our renowned contract packs to our hospital customers. As well as a product list for the Wave 14b contract change which starts on 1st October for certain regions, there’s a selection of refreshments, and stationery for NHS pharmacy departments to use during the changeover.   We…

Read more
https://www.mawdsleys.co.uk/news/mawdsleys-and-oncoscience-launch-a-named-patient-program-for-cimaher-nimotuzumab-in-the-uk-and-ireland/ thumbnail image Mawdsleys and Oncoscience launch a Named Patient Program for CIMAher®

Mawdsleys and Oncoscience GMbH have launched a Named Patient Supply Program to allow Oncologists in the United Kingdom (UK) and Ireland to obtain access to CIMAher® (Nimotuzumab) on an unlicensed basis for the treatment of various types of cancer.   Nimotuzumab has been approved for marketing in 25 different countries worldwide for a variety of…

Read more